CEimpact Podcast

Coronary Artery Disease Guideline Update

September 04, 2023 CEimpact
CEimpact Podcast
Coronary Artery Disease Guideline Update
Show Notes

The American Heart Association updated the Coronary Artery Disease (CAD) guidelines for the first time in a decade. Join host, Geoff Wall, as he evaluates what's new in CAD pharmacotherapy.
The GameChanger
CAD pharmacotherapy is dependent on aggressive lipid management whereas antiplatelet and beta-blocker therapy is now more nuanced.
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Jul 20. doi: 10.1161/CIR.0000000000001168. Epub ahead of print. PMID: 37471501.


Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)

CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the new AHA coronary artery disease (CAD) guidelines
2. Apply AHA CAD guidelines for medical management of a patient with stable CAD

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-295-H01-P
Initial release date: 9/4/2023
Expiration date: 9/4/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:

Download the CEimpact App for Free Continuing Education + so much more!